Long-acting Sandostatin delays progression of neuroendocrine tumors

Long-acting Sandostatin delays progression of neuroendocrine tumors. Steve Jobs may want to take notice of a result presented at the 2009 Gastrointestinal Cancers Symposium: Sandostatin LAR delays progression of metastatic neuroendocrine tumors. These smaller tumor-focused meetings such as San Antonio for breast cancer and now the annual GI Cancers Symposium frequently present higher quality data than the larger ASCO annual meeting. Cancer information is getting even more fragmented though the pace of discovery is about the same as it's been in the past. Sandostatin LAR may be a good drug but it has a very user-unfriendly pricetag. It's one of these shots that costs as much as a car and it's given once a month. It's priced based on the idea that giving regular Sandostatin three times a day for a month would cost X so we make the long-acting Sandostatin LAR cost X-$100 or something like that. The MBAs probably have a name for this. This is the first time I can recall that something delayed progression in neuroendocrine tumors and this time the benefit is impressive: 8 month improvement in progression over double the time of freedom from progression. Hate to sound like an industry shill but that's a nice benefit.